SUSAN ABUGHOSH to Medicare
This is a "connection" page, showing publications SUSAN ABUGHOSH has written about Medicare.
Connection Strength
1.687
-
A Pharmacist Telephone Intervention to Identify Adherence Barriers and Improve Adherence Among Nonadherent Patients with Comorbid Hypertension and Diabetes in a Medicare Advantage Plan. J Manag Care Spec Pharm. 2016 Jan; 22(1):63-73.
Score: 0.374
-
Effect of initial combination therapy vs. step-therapy on adherence and persistence in drug na?ve type 2 diabetes patients. J Diabetes Complications. 2025 Sep; 39(9):109080.
Score: 0.179
-
Delirium event and associated treatment modifications among older adults with Alzheimer's disease: An interrupted time-series analysis of Medicare data. Pharmacotherapy. 2024 Oct; 44(10):782-793.
Score: 0.171
-
Group-based trajectory modeling to identify adherence patterns for direct oral anticoagulants in Medicare beneficiaries with atrial fibrillation: a real-world study on medication adherence. Int J Clin Pharm. 2024 Dec; 46(6):1525-1535.
Score: 0.170
-
Group based trajectory modeling to assess adherence to oral anticoagulants among atrial fibrillation patients with comorbidities: a retrospective study. Int J Clin Pharm. 2022 Aug; 44(4):966-974.
Score: 0.147
-
Evaluating adherence to concomitant diabetes, hypertension, and hyperlipidemia treatments and intermediate outcomes among elderly patients using marginal structural modeling. Pharmacotherapy. 2022 07; 42(7):518-528.
Score: 0.146
-
Adherence to concomitant diabetes, hypertension, and hyperlipidemia treatments among older patients. J Am Pharm Assoc (2003). 2022 Jul-Aug; 62(4):1351-1358.
Score: 0.144
-
Evaluating trajectories of statin adherence after a motivational interviewing intervention. J Am Pharm Assoc (2003). 2020 Nov - Dec; 60(6):892-898.
Score: 0.128
-
Cumulative Anticholinergic Burden and its Predictors among Older Adults with Alzheimer's Disease Initiating Cholinesterase Inhibitors. Drugs Aging. 2024 Apr; 41(4):339-355.
Score: 0.041
-
Overall survival associated with CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer in the United States: A SEER-Medicare population-based study. Cancer. 2023 04 01; 129(7):1051-1063.
Score: 0.038
-
Impact of CDK4/6 inhibitors on chemotherapy utilization in earlier therapy lines for HR+/HER2- metastatic breast cancer in the United States. Breast Cancer Res Treat. 2023 Feb; 198(1):159-166.
Score: 0.038
-
Dose-dependent relation between metformin and the risk of hormone receptor-positive, her2-negative breast cancer among postmenopausal women with type-2 diabetes. Breast Cancer Res Treat. 2022 Oct; 195(3):421-430.
Score: 0.037
-
Effect of coverage gap on healthcare utilization among Medicare beneficiaries with chronic obstructive pulmonary disorder. Curr Med Res Opin. 2019 02; 35(2):321-328.
Score: 0.028
-
Evaluating Pharmacist-Written Recommendations to Providers in a Medicare Advantage Plan: Factors Associated with Provider Acceptance. J Manag Care Spec Pharm. 2016 Jan; 22(1):49-55.
Score: 0.023
-
CMF-regimen preferred as first-course chemotherapy for older and sicker women with breast cancer: Findings from a SEER-Medicare-based population study. Am J Clin Oncol. 2015 Apr; 38(2):165-73.
Score: 0.022